Originally developed for spinal cord injuries, KCL-286 leverages biological overlaps between central nervous system trauma and Alzheimer's. Because the drug has already completed Phase 1 human safety and tolerability trials, researchers suggest the timeline for further clinical testing may be significantly accelerated compared to new drug candidates.